Harvala Heli, Johannesen Caroline K, Benschop Kimberley S M, Saxentoff Eugene V, Huseynov Shahin, Hagan José E, Fischer Thea K
Institute of Biomedicine, Medical Faculty, University of Turku, Finland.
Microbiology Services, National Health Service (NHS) Blood and Transplant, London, United Kingdom.
Lancet Reg Health Eur. 2025 Apr 11;53:101292. doi: 10.1016/j.lanepe.2025.101292. eCollection 2025 Jun.
While the association of polioviruses with paralytic disease is well-documented and closely monitored via the Global Polio Eradication initiative, monitoring of the circulation and role of other non-polio enteroviruses in paralytic and non-paralytic disease has not received the same priority. We have assessed assess the role and potential effectiveness of the current enterovirus surveillance systems in the final stages of polio eradication.
We compared data on enterovirus circulation and clinical associations reported to the World Health Organization (WHO) Regional Office for Europe via the acute flaccid paralysis (AFP), clinical enterovirus, and environmental surveillance systems along with that collected by the European Non-Polio Enterovirus Network (ENPEN), 2015-2022.
This 8-year study analysed data from 63,659 samples from diagnosed enterovirus infections reported by 48 European countries, of which 27,699 were successfully typed (43.5%). This revealed the circulation of 67 individual enterovirus types primarily reported via ENPEN (85%; 19,712/23,220), whereas most poliovirus infections were reported via WHO (99.9%; 4484/4489). Only 20% of non-polio enterovirus positive AFP cases reported to WHO were successfully typed (105/544). Clinical data linked to these cases underscored the severity of paralytic non-polio enterovirus infections with 12 deaths compared to three deaths caused by poliovirus infections during the same study period.
The study documents non-polio enterovirus infections as a frequent cause of paralysis in Europe. Implementation of standardized monitoring and reporting of all enteroviruses identified from severely ill patients, including those with paralysis, would enhance our understanding of the burden of non-polio enterovirus infections without compromising poliovirus surveillance.
This study was funded by WHO Regional Office for Europe and received financial support from the Bill and Melinda Gates Foundation.
虽然脊髓灰质炎病毒与麻痹性疾病之间的关联已有充分记录,并通过全球根除脊髓灰质炎行动进行密切监测,但对其他非脊髓灰质炎肠道病毒在麻痹性和非麻痹性疾病中的传播情况及作用的监测并未得到同等重视。我们评估了当前肠道病毒监测系统在脊髓灰质炎根除最后阶段的作用和潜在效果。
我们比较了2015年至2022年期间通过急性弛缓性麻痹(AFP)、临床肠道病毒和环境监测系统以及欧洲非脊髓灰质炎肠道病毒网络(ENPEN)收集的,向世界卫生组织(WHO)欧洲区域办事处报告的肠道病毒传播和临床关联数据。
这项为期8年的研究分析了48个欧洲国家报告的63659份确诊肠道病毒感染样本的数据,其中27699份成功分型(43.5%)。这揭示了主要通过ENPEN报告的67种个体肠道病毒类型的传播情况(85%;19712/23220),而大多数脊髓灰质炎病毒感染是通过WHO报告的(99.9%;4484/4489)。向WHO报告的非脊髓灰质炎肠道病毒阳性AFP病例中,只有20%成功分型(105/544)。与这些病例相关的临床数据突显了麻痹性非脊髓灰质炎肠道病毒感染的严重性,在同一研究期间有12人死亡,而脊髓灰质炎病毒感染导致3人死亡。
该研究证明非脊髓灰质炎肠道病毒感染是欧洲麻痹的常见原因。对包括麻痹患者在内的重症患者中发现的所有肠道病毒实施标准化监测和报告,将增进我们对非脊髓灰质炎肠道病毒感染负担的了解,同时不影响脊髓灰质炎病毒监测。
本研究由WHO欧洲区域办事处资助,并获得了比尔及梅琳达·盖茨基金会的资金支持。